On June 4, 2024, Sun Pharmaceutical Industries Ltd, along with Philogen S.p.A., announced that Nidlegy™, an investigational treatment for neoadjuvant melanoma, has had its Marketing Authorization Application (MAA) submitted to the European Medicines Agency (EMA). Based on data from the Phase 3 PIVOTAL study (PHL19IL2TNF-02/15) and Phase 2 trial (PHL19IL2TNF-02/12), the submission marks a significant …